Effects of Insomnia on Simulated Driving (MK-0000-183-00)
Primary Purpose
Insomnia
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Placebo/ethanol (blinded)
Sponsored by
About this trial
This is an interventional other trial for Insomnia focused on measuring insomnia, insomniacs, simulated driving, alcohol, ethanol
Eligibility Criteria
Inclusion Criteria A patient or subject may participate in the study if, at least, the ALL of the criteria below are met.
The participant:
- Is a male or female of non-childbearing potential and 65 years of age or older at prestudy (screening);
- Has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months prior to screening;
- Has a current valid driver's license;
- Their regular bedtime is between 9 pm (21:00) and 12 am (00:00);
- During the study, are willing to refrain from napping;
Additionally, a primary insomnia patient must meet the following inclusion criteria:
- Has a diagnosis of Primary Insomnia;
- Reports total sleep time of < 6 hours on at least 3 out of 7 nights each week during the 4 weeks prior to screening;
- Reports spending 6 to 9 hours nightly in bed on at least 3 out of 7 nights each week during the 4 weeks prior to screening.
Exclusion Criteria :
A patient may not participate in the study if ANY of the criteria below (among others determined by the study staff) apply.
The participant:
- Has visual or auditory impairment;
- Has a history of clinically significant endocrine (including diabetes), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases;
- Has a history of neoplastic disease ;
- Is taking, or plans to take, one or more of the following medications (non-inclusive), within the 2 weeks prior to screening and throughout the course of the study: Centrally acting anticholinergics or antihistamines; Melatonin; Anticonvulsants; Antipsychotics; Anxiolytics; Benzodiazepines; Hypnotics; Any CNS depressants; Over-the-counter medications that could affect sleep; Stimulants; Diet pills; Anti-depressants; Disulfiram;
- Has a positive screening urine drug test (e.g., positive for benzodiazepines, cannabinoids, cocaine, etc.);
- Has a lifetime history of bipolar disorder, a psychotic disorder, or posttraumatic stress disorder or a psychiatric condition requiring treatment with a prohibited medication; or other current psychiatric condition that, in the investigator's opinion, would interfere with the subject/patient's ability to participate in the study ;
- Has evidence of suicidality;
- Has a history of transmeridian travel (across > 3 time zones or > 3 hour time difference) within two weeks prior to screening or anticipates transmeridian travel during the study;
- Has a history of shift work (defined as permanent night shift or rotating day/night shift work) within the past two weeks prior to screening or anticipates need to perform shift work during the study;
- Has a history or diagnosis of any of following conditions, in the opinion of the investigator: Narcolepsy; Cataplexy (familial or idiopathic); Circadian Rhythm Sleep Disorder; Parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder, and REM behavior disorder; Sleep-related Breathing Disorder (obstructive or central sleep apnea syndrome, central alveolar hypoventilation syndrome); Periodic Limb Movement Disorder; Restless Legs Syndrome; Primary Hypersomia; Excessive Daytime Sleepiness (EDS), not attributable to Primary Insomnia
- Has a recent and/or active history of a confounding neurological disorder, including but not limited to: seizure disorder, stroke, transient ischemic attack, multiple sclerosis, cognitive impairment, or significant head trauma with sustained loss of consciousness and residual impairment within the last 10 years;
- Has a history of allergy, exceptional sensitivity, or adverse reaction to alcohol;
- Has a significant history of motion sickness or demonstrates significant simulator sickness during practice drives at screening;
- Consumes excessive amounts of alcohol or subject or patient consumes alcohol to promote sleep (i.e., within 3 hours before going to bed);
- Has never consumed alcohol;
- Consumes excessive amounts of coffee, tea, cola, or other caffeinated beverages.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Primary insomnia patients and healthy subjects
Arm Description
Elderly participants, including primary insomnia patients and healthy subjects
Outcomes
Primary Outcome Measures
Simulated driving variables
Simulated driving variables which may include (standard deviation of lane position (SDLP), speed deviation, lane excursions, or a composite score of several driving variables).
Secondary Outcome Measures
Full Information
NCT ID
NCT01209728
First Posted
September 24, 2010
Last Updated
June 10, 2019
Sponsor
Merck Sharp & Dohme LLC
1. Study Identification
Unique Protocol Identification Number
NCT01209728
Brief Title
Effects of Insomnia on Simulated Driving (MK-0000-183-00)
Official Title
A Randomized Clinical Trial to Study the Effects of Simulated Driving on Primary Insomniacs
Study Type
Interventional
2. Study Status
Record Verification Date
June 2019
Overall Recruitment Status
Completed
Study Start Date
October 1, 2010 (Actual)
Primary Completion Date
September 1, 2011 (Actual)
Study Completion Date
September 1, 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a double-blind, parallel design study in elderly primary insomnia patients and demographically matched controls. The objectives if this study are primarily: 1. To determine if functional deficits in simulated driving performance can be demonstrated in primary insomnia patients, and detected in healthy volunteers, impaired by alcohol; and secondarily: 2. To compare simulated driving performance deficits in elderly primary insomnia patients to those in healthy elderly volunteers impaired by alcohol, for at least one of the following driving endpoints: standard deviation of lane position (SDLP), standard deviation of speed (speed deviation), lane excursions, and a driving composite score.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia
Keywords
insomnia, insomniacs, simulated driving, alcohol, ethanol
7. Study Design
Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
76 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Primary insomnia patients and healthy subjects
Arm Type
Experimental
Arm Description
Elderly participants, including primary insomnia patients and healthy subjects
Intervention Type
Other
Intervention Name(s)
Placebo/ethanol (blinded)
Other Intervention Name(s)
Placebo or ethanol (blinded)
Intervention Description
Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
Primary Outcome Measure Information:
Title
Simulated driving variables
Description
Simulated driving variables which may include (standard deviation of lane position (SDLP), speed deviation, lane excursions, or a composite score of several driving variables).
Time Frame
Evaluated on, up to, 3 different days, with 2 driving sessions of ~65 minutes each day.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria A patient or subject may participate in the study if, at least, the ALL of the criteria below are met.
The participant:
Is a male or female of non-childbearing potential and 65 years of age or older at prestudy (screening);
Has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months prior to screening;
Has a current valid driver's license;
Their regular bedtime is between 9 pm (21:00) and 12 am (00:00);
During the study, are willing to refrain from napping;
Additionally, a primary insomnia patient must meet the following inclusion criteria:
Has a diagnosis of Primary Insomnia;
Reports total sleep time of < 6 hours on at least 3 out of 7 nights each week during the 4 weeks prior to screening;
Reports spending 6 to 9 hours nightly in bed on at least 3 out of 7 nights each week during the 4 weeks prior to screening.
Exclusion Criteria :
A patient may not participate in the study if ANY of the criteria below (among others determined by the study staff) apply.
The participant:
Has visual or auditory impairment;
Has a history of clinically significant endocrine (including diabetes), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases;
Has a history of neoplastic disease ;
Is taking, or plans to take, one or more of the following medications (non-inclusive), within the 2 weeks prior to screening and throughout the course of the study: Centrally acting anticholinergics or antihistamines; Melatonin; Anticonvulsants; Antipsychotics; Anxiolytics; Benzodiazepines; Hypnotics; Any CNS depressants; Over-the-counter medications that could affect sleep; Stimulants; Diet pills; Anti-depressants; Disulfiram;
Has a positive screening urine drug test (e.g., positive for benzodiazepines, cannabinoids, cocaine, etc.);
Has a lifetime history of bipolar disorder, a psychotic disorder, or posttraumatic stress disorder or a psychiatric condition requiring treatment with a prohibited medication; or other current psychiatric condition that, in the investigator's opinion, would interfere with the subject/patient's ability to participate in the study ;
Has evidence of suicidality;
Has a history of transmeridian travel (across > 3 time zones or > 3 hour time difference) within two weeks prior to screening or anticipates transmeridian travel during the study;
Has a history of shift work (defined as permanent night shift or rotating day/night shift work) within the past two weeks prior to screening or anticipates need to perform shift work during the study;
Has a history or diagnosis of any of following conditions, in the opinion of the investigator: Narcolepsy; Cataplexy (familial or idiopathic); Circadian Rhythm Sleep Disorder; Parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder, and REM behavior disorder; Sleep-related Breathing Disorder (obstructive or central sleep apnea syndrome, central alveolar hypoventilation syndrome); Periodic Limb Movement Disorder; Restless Legs Syndrome; Primary Hypersomia; Excessive Daytime Sleepiness (EDS), not attributable to Primary Insomnia
Has a recent and/or active history of a confounding neurological disorder, including but not limited to: seizure disorder, stroke, transient ischemic attack, multiple sclerosis, cognitive impairment, or significant head trauma with sustained loss of consciousness and residual impairment within the last 10 years;
Has a history of allergy, exceptional sensitivity, or adverse reaction to alcohol;
Has a significant history of motion sickness or demonstrates significant simulator sickness during practice drives at screening;
Consumes excessive amounts of alcohol or subject or patient consumes alcohol to promote sleep (i.e., within 3 hours before going to bed);
Has never consumed alcohol;
Consumes excessive amounts of coffee, tea, cola, or other caffeinated beverages.
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
IPD Sharing URL
http://engagezone.msd.com/ds_documentation.php
Citations:
PubMed Identifier
26240742
Citation
Simen AA, Gargano C, Cha JH, Drexel M, Bautmans A, Heirman I, Laethem T, Hochadel T, Gheyle L, Bleys K, Beals C, Stoch A, Kay GG, Struyk A. A randomized, crossover, placebo-controlled clinical trial to assess the sensitivity of the CRCDS Mini-Sim to the next-day residual effects of zopiclone. Ther Adv Drug Saf. 2015 Jun;6(3):86-97. doi: 10.1177/2042098615579314.
Results Reference
result
Learn more about this trial
Effects of Insomnia on Simulated Driving (MK-0000-183-00)
We'll reach out to this number within 24 hrs